Heart Failure

Men hospitalized with HF with preserved ejection fraction experienced elevated risk for 1-year all-cause mortality compared with women, researchers reported.

As clinicians around the world rapidly transitioned from in-person to telehealth visits during the COVID-19 pandemic, it required managing many changes at once.

From 2008 to 2017, overall rates of recurrent MI declined among men and women in the U.S. in the 365 days after discharge, according to research published in Circulation.

The FDA has fast tracked the development of empagliflozin to prevent hospitalization for heart failure and reduce risk for all-cause mortality in adults with and without diabetes with a previous myocardial infarction.

Patients with atrial fibrillation who received nonrecommended doses of direct oral anticoagulants had increased risk for death compared with those who received recommended doses, according to new data from the GARFIELD-AF registry.

Among patients with type 2 diabetes and atherosclerotic CVD, the SGLT2 inhibitor ertugliflozin reduced risk for first and total HF events compared with placebo, according to new data from the VERTIS CV study.

Autologous cell-based therapy in patients with acute MI may decrease HF hospitalization, according to the BAMI trial, which was converted to an observational trial due to low patient recruitment.

Prior influenza or pneumococcal vaccination may be associated with lower rates of in-hospital mortality among patients with HF, according to research presented at the virtual European Society of Cardiology Congress.

Patients with stable ischemic heart disease and HF and/or left ventricular dysfunction experienced worse outcomes compared with patients who did not and may benefit more from invasive treatment strategies, researchers reported.

The PARALLAX trial of sacubitril/valsartan for HF with preserved ejection fraction met one of its two co-primary endpoints, showing a reduction in NT-proBNP, but no additional benefit on 6-minute walk distance and functional class.